Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

  • Mithra strengthens its presence in the fast-growing Chilean market with an agreement for commercialization of the hormone treatment Tibelia® with Saval Pharmaceuticals
  • Tibelia® is currently marketed in about ten countries through existing license and supply agreements and just adds an additional market in Spain after winning a public tender

Liege, Belgium, 05 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it has entered into a license and supply agreement with Saval Pharmaceuticals to commercialize Tibelia® in Chile.